Accelerating Diagnostics in a Time of Crisis The Response to COVID-19 and a Roadmap for Future Pandemics
Book contents
- Accelerating Diagnostics in a Time of Crisis
- Accelerating Diagnostics in a Time of Crisis
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgments
- Introduction
- Chapter 1 Early Detection, Response, and Surveillance of the COVID-19 Pandemic Crisis
- Chapter 2 Immunology of COVID-19 and Ineffective Immunity
- Chapter 3 Clinical Management: A Roadmap Based on One New York City Hospital’s Response to the COVID-19 Pandemic
- Chapter 4 Contribution of RADx® Tech to the Rapid Development of COVID-19 Diagnostic Tests
- Chapter 5 Coordination of Resources for the Manufacturing and Deployment of COVID-19 Diagnostic Assays
- Chapter 6 Quality and Risk Management Processes for Diagnostic Assays during an Emergency Pandemic Response
- Chapter 7 Development of Assays to Diagnose COVID-19
- Chapter 8 Laboratory Verification and Clinical Validation of COVID-19 Diagnostic Assays
- Chapter 9 Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants
- Chapter 10 The RADx® Regulatory Core and Its Role in COVID-19 Emergency Use Authorizations
- Chapter 11 Commercialization and Market Assessment of COVID-19 Assays
- Chapter 12 Testing Strategies to Mitigate COVID-19 Disease Spread
- Chapter 13 A Pandemic Not Just of Infection but of Inequality: The Social Impact of COVID-19
- Chapter 14 Summary and Path Forward for Future Pandemics
- Index
- References
Chapter 4 - Contribution of RADx® Tech to the Rapid Development of COVID-19 Diagnostic Tests
Published online by Cambridge University Press: 06 January 2024
Book contents
- Accelerating Diagnostics in a Time of Crisis
- Accelerating Diagnostics in a Time of Crisis
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgments
- Introduction
- Chapter 1 Early Detection, Response, and Surveillance of the COVID-19 Pandemic Crisis
- Chapter 2 Immunology of COVID-19 and Ineffective Immunity
- Chapter 3 Clinical Management: A Roadmap Based on One New York City Hospital’s Response to the COVID-19 Pandemic
- Chapter 4 Contribution of RADx® Tech to the Rapid Development of COVID-19 Diagnostic Tests
- Chapter 5 Coordination of Resources for the Manufacturing and Deployment of COVID-19 Diagnostic Assays
- Chapter 6 Quality and Risk Management Processes for Diagnostic Assays during an Emergency Pandemic Response
- Chapter 7 Development of Assays to Diagnose COVID-19
- Chapter 8 Laboratory Verification and Clinical Validation of COVID-19 Diagnostic Assays
- Chapter 9 Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants
- Chapter 10 The RADx® Regulatory Core and Its Role in COVID-19 Emergency Use Authorizations
- Chapter 11 Commercialization and Market Assessment of COVID-19 Assays
- Chapter 12 Testing Strategies to Mitigate COVID-19 Disease Spread
- Chapter 13 A Pandemic Not Just of Infection but of Inequality: The Social Impact of COVID-19
- Chapter 14 Summary and Path Forward for Future Pandemics
- Index
- References
Summary
Rapid Acceleration of Diagnostics (RADx®) Tech was the key diagnostics component of a three-pronged national strategy, including vaccines and therapeutics, to respond to the COVID-19 pandemic. Unprecedented in the scale of its mission, its budget, its accelerated time frame, the extent of cross-government agency collaboration and information exchange, and the blending of business, academic, and investment best practices, RAD Tech successfully launched dozens of US Food and Drug Administration Emergency Use Authorization diagnostic tests, established a new model for rapidly translating diagnostic tests from the laboratory to the marketplace, and accelerated public acceptance of home-based diagnostic tests. This chapter provides an overview of the processes utilized by RADx Tech during the COVID-19 pandemic to improve clinical laboratory tests and identify, evaluate, support, validate, and commercialize innovative point-of-care and home-based tests that directly detected the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
Keywords
- Type
- Chapter
- Information
- Accelerating Diagnostics in a Time of CrisisThe Response to COVID-19 and a Roadmap for Future Pandemics, pp. 74 - 87Publisher: Cambridge University PressPrint publication year: 2024
References
Taylor, R., Health officials Senate testimony transcript on new tests for COVID-19 (May 7, 2020). https://tinyurl.com/fk9txwm7.Google Scholar
Alexander, L. and Blunt, R., Opinion: we need more covid-19 tests. We propose a “shark tank” to get us there, Washington Post (April 20, 2020). https://tinyurl.com/bdf3ecma.Google Scholar
Carleton, P.F., Schachter, S., Lash, T. B., et al., Point-of-Care Technology Research Network: an evolving model for collaborative translational research in biomedical engineering. Curr Opin Biomed Eng, 11 (2019), 145–148.CrossRefGoogle Scholar
Tromberg, B. J., Schwetz, T. A., Pérez-Stable, E. J., et al., Rapid scaling up of Covid-19 diagnostic testing in the United States – the NIH RADx initiative. N Engl J Med, 383, 11 (2020), 1071–1077.CrossRefGoogle ScholarPubMed
Collins, J. M., Collins, M. R., McKenzie, T., and Marino, M., The role of CoLab and GAITS in enabling the RADx Tech program. IEEE Open J Eng Med Biol, 2 (2021), 119–124.CrossRefGoogle ScholarPubMed
Gibson, L., Fahey, N., Hafer, N., et al., The RADx Tech Clinical Studies Core: a model for academic based clinical studies. IEEE Open J Eng Med Biol, 2 (2021), 152–157.CrossRefGoogle Scholar
Soni, A., Herbert, C., Filippaios, A., et al., Comparison of rapid antigen tests’ performance between delta and omicron variants of SARS-CoV-2: a secondary analysis from a serial home self-testing study. Ann Intern Med, 175, 12 (2022), 1685–1692.CrossRefGoogle ScholarPubMed
Soni, A., Herbert, C., Lin, H., et al., Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv (2022), https://doi.org/10.1101/2022.08.05.22278466.CrossRefGoogle Scholar
Robinson, M., Gaydos, C., Van Der Pol, B., et al., The Clinical Review Committee: impact of the development of in vitro diagnostic tests for SARS-CoV-2 within RADx Tech. IEEE Open J Eng Med Biol, 2 (2021), 138–141.CrossRefGoogle ScholarPubMed
Tessier, P., Dempsey, M., Collins, J., and Schachter, S., RADx Tech Viability and Steering Panels: a model for MedTech translational grant review. IEEE Open J Eng Med Biol, 2 (2021), 125–130.CrossRefGoogle Scholar
Dempsey, M., Tessier, P., Collins, J., and Caro, E., The RADx Tech deep dive and work package 1 process. IEEE Open J Eng Med Biol, 2 (2021), 131–137.Google Scholar
FDA, At-Home COVID-19 Antigen Tests-Take Steps to Reduce Your Risk of False Negative Results: FDA Safety Communication. Updated November 17, 2022 (2022). https://tinyurl.com/5bdn25y4.Google Scholar
POCTRN, RADx Tech webinar series 2023. www.poctrn.org/radx-webinars (accessed January 29, 2023).Google Scholar
Akay, M., Subramaniam, S., Brennan, C., et al., Healthcare innovations to address the challenges of the COVID-19 pandemic. IEEE J Biomed Health Inform, 26, 7 (2022), 3294–3302.CrossRefGoogle ScholarPubMed